EUVIMEDEUVIMED entdecken
Crossref

Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS

Xiaoxia An, Yanting Mao, Ali Fan, Ting Ma iD

Rapid Communications in Mass Spectrometry · 2025

DOI: 10.1002/rcm.10141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Xiaoxia An und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Receptors, Fibroblast Growth Factor. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Resigratinib, a potent fibroblast growth factor receptor (FGFR) inhibitor, is under clinical development for solid tumors such as cholangiocarcinoma. However, data on its hepatic metabolism remain limited. To support further development, this study aimed to characterize its in vitro metabolism using rat, dog, monkey, and human liver microsomes.

Methods

A sensitive and robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was validated for quantifying resigratinib in liver microsomes. Metabolite characterization was performed using LC coupled with benchtop Orbitrap high‐resolution mass spectrometry (LC‐Orbitrap‐HRMS) in full‐scan MS/dd‐MS 2 and parallel reaction monitoring (PRM). This approach enabled accurate mass measurement, chemical formula assignment, and structural elucidation via MS 2 fragmentation interpretation.

Results

The established method exhibited excellent linearity over the concentration range of 1.0–1000 nM. Resigratinib displayed low clearance in dog ( t 1/2 = 91.2 min), intermediate clearance in rat ( t 1/2 = 20.2 min), and high clearance in monkey ( t 1/2 = 6.8 min) and human ( t 1/2 = 14.0 min) systems. Ten metabolites were identified, with M3 ( bis ‐demethylation), M5 ( O ‐demethylation), and M9 ( N ‐demethylation) identified as the major metabolites. Recombinant human cytochrome P450 enzyme analysis and chemical inhibition studies indicated that CYP3A4 is the predominant enzyme responsible for resigratinib metabolism.

Conclusion

This study presents the first integrated analytical approach, combining LC–MS/MS and LC‐Orbitrap‐HRMS, for the in vitro metabolic assessment of resigratinib. The observed metabolic profiles provide an essential foundation for further toxicological and clinical investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryReceptors, Fibroblast Growth FactorAnimalsDogsMicrosomes, LiverHumansRatsChromatography, LiquidRats, Sprague-DawleyMaleMacaca fascicularisHaplorhiniMetabolomeLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

CYP3A4fibroblast growth factor receptorhigh‐resolution mass spectrometrymetabolic profilesresigratinib

Substanzen

Receptors, Fibroblast Growth Factor

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
  • TriApex Laboratories Co. Ltd, Nanjing, China.
  • School of Pharmaceutical Science, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Pingyuan Laboratory, Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Ting Ma

Zitieren

APA

An, X., Mao, Y., Fan, A., & Ma, T. (2025). Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10141

Vancouver

An X, Mao Y, Fan A, Ma T. Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10141

BibTeX
@article{An2025,
  author = {An, Xiaoxia and Mao, Yanting and Fan, Ali and Ma, Ting},
  title = {Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS},
  journal = {Rapid Communications in Mass Spectrometry},
  year = {2025},
  doi = {10.1002/rcm.10141}
}
Kostenlos starten →